Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CINCINNATI--(BUSINESS WIRE)--Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce that MLS manufactured an H1N1 influenza A challenge stock for Immune Targeting Systems, Ltd. Immune Targeting Systems contracted Meridian Life Science to manufacture the influenza A challenge stock resulting in a 12-month, highly collaborative production program culminating in the successful release of the challenge stock. Meridian Life Science manufactured the influenza A challenge stock according to appropriate current Good Manufacturing Practices (cGMP) parts 21 CFR Parts 210 and 211 for use in Phase 1 human clinical trials to the desired specifications and under aggressive timelines; allowing Immune Targeting Systems to meet critical clinical development timelines.
Help employers find you! Check out all the jobs and post your resume.
